Onx­eo shares blitzed af­ter PhI­II liv­er can­cer study flops

Shares of Paris-based Onx­eo were blitzed af­ter the biotech re­port­ed that its Phase III can­cer study had failed.

Study­ing Li­vatag (dox­oru­bicine Trans­drug) in com­par­i­son with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER